Literature DB >> 35385696

Making anticoagulation safer.

David Gailani1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35385696      PMCID： PMC9540354          DOI： 10.1016/S0140-6736(22)00563-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   202.731


× No keyword cloud information.
  12 in total

Review 1.  Rare bleeding disorders - bleeding assessment tools, laboratory aspects and phenotype and therapy of FXI deficiency.

Authors:  P James; O Salomon; D Mikovic; F Peyvandi
Journal:  Haemophilia       Date:  2014-05       Impact factor: 4.287

2.  Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial.

Authors:  Jeffrey I Weitz; Rupert Bauersachs; Bastian Becker; Scott D Berkowitz; Maria C S Freitas; Michael R Lassen; Carola Metzig; Gary E Raskob
Journal:  JAMA       Date:  2020-01-14       Impact factor: 56.272

3.  Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.

Authors:  Jonathan P Piccini; Valeria Caso; Stuart J Connolly; Keith A A Fox; Jonas Oldgren; W Schuyler Jones; Diana A Gorog; Václav Durdil; Thomas Viethen; Christoph Neumann; Hardi Mundl; Manesh R Patel
Journal:  Lancet       Date:  2022-04-03       Impact factor: 79.321

4.  Milvexian for the Prevention of Venous Thromboembolism.

Authors:  Jeffrey I Weitz; John Strony; Walter Ageno; David Gailani; Elaine M Hylek; Michael R Lassen; Kenneth W Mahaffey; Ravi S Notani; Robin Roberts; Annelise Segers; Gary E Raskob
Journal:  N Engl J Med       Date:  2021-11-15       Impact factor: 176.079

5.  Factor XI antisense oligonucleotide for prevention of venous thrombosis.

Authors:  Harry R Büller; Claudette Bethune; Sanjay Bhanot; David Gailani; Brett P Monia; Gary E Raskob; Annelise Segers; Peter Verhamme; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2014-12-07       Impact factor: 91.245

6.  Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action.

Authors:  Diane K Wysowski; Parivash Nourjah; Lynette Swartz
Journal:  Arch Intern Med       Date:  2007-07-09

Review 7.  An update on factor XI structure and function.

Authors:  Bassem M Mohammed; Anton Matafonov; Ivan Ivanov; Mao-Fu Sun; Qiufang Cheng; S Kent Dickeson; Chan Li; David Sun; Ingrid M Verhamme; Jonas Emsley; David Gailani
Journal:  Thromb Res       Date:  2017-10-10       Impact factor: 3.944

8.  Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation.

Authors:  M Cecilia Bahit; Renato D Lopes; Daniel M Wojdyla; Claes Held; Michael Hanna; Dragos Vinereanu; Elaine M Hylek; Freek Verheugt; Shinya Goto; John H Alexander; Lars Wallentin; Christopher B Granger
Journal:  Heart       Date:  2016-10-24       Impact factor: 5.994

9.  Abelacimab for Prevention of Venous Thromboembolism.

Authors:  Peter Verhamme; B Alexander Yi; Annelise Segers; Janeen Salter; Daniel Bloomfield; Harry R Büller; Gary E Raskob; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2021-07-19       Impact factor: 91.245

Review 10.  Effects of rivaroxaban and warfarin on the risk of gastrointestinal bleeding and intracranial hemorrhage in patients with atrial fibrillation: Systematic review and meta-analysis.

Authors:  Hongcheng Jiang; Yue Jiang; Haotian Ma; Hesong Zeng; Jiagao Lv
Journal:  Clin Cardiol       Date:  2021-07-24       Impact factor: 2.882
View more
  1 in total

Review 1.  Hemostasis in neonatal ECMO.

Authors:  Valeria Cortesi; Genny Raffaeli; Giacomo S Amelio; Ilaria Amodeo; Silvia Gulden; Francesca Manzoni; Gaia Cervellini; Andrea Tomaselli; Marta Colombo; Gabriella Araimo; Andrea Artoni; Stefano Ghirardello; Fabio Mosca; Giacomo Cavallaro
Journal:  Front Pediatr       Date:  2022-08-26       Impact factor: 3.569
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.